Glenmark Pharmaceuticals
GLENMARK
₹ 1,023.95
₹ 24.30
2.43%
Glenmark Pharmaceuticals Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | - |
| Weekly | -2.79% | 20,34,547 |
| Monthly | -1.86% | 1,11,50,994 |
Glenmark Pharmaceuticals Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| GLENMARK | - | -2.79% | -1.86% |
| Index | - | -1.46% | -2.67% |
| Peer Avg. | - | -3.10% | -0.57% |
*Avg of index constituents
Glenmark Pharmaceuticals Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| GLENMARK | 9.75 | 1.06 | 5.58 | 12.50 | 13.72 | 0.59 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
*Avg of index constituents
Glenmark Pharmaceuticals Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 10.01% | 11.77% | 12.50 | 13.72 |
| FY '20-21 | 7.79% | 23.39% | 13.29 | 13.92 |
| FY '19-20 | 1.82% | -16.30% | 12.05 | 12.64 |
Glenmark Pharmaceuticals Shareholding Pattern
Promoters : 46.65%
FII : 24.12%
DII : 10.96%
Public : 18.27%
Others : 0%
Glenmark Pharmaceuticals Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 10,223.24 | 8,218.98 | 2,394.91 | 1,495.72 |
| FY '20-21 | 9,255.93 | 7,268.57 | 2,210.59 | 1,309.77 |
| FY '19-20 | 8,676.80 | 7,175.64 | 1,884.35 | 1,065.26 |
All values are in crores
Glenmark Pharmaceuticals Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| GLENMARK | 10,223.24 | 8,218.98 | 2,394.91 | 1,495.72 |
| CAMPUS | 1,194.18 | 952.43 | 244.15 | 108.15 |
| BLUESTARCO | 5,711.28 | 5,417.27 | 354.92 | 147.32 |
All values are in crores
Glenmark Pharmaceuticals Similar Stocks
Cipla
CIPLA
₹ 1,339.55
- ₹ 19.25
-1.41%
Dr. Reddy's Laboratories
DRREDDY
₹ 5,921.00
₹ 43.65
0.74%
Lupin
LUPIN
₹ 1,608.55
₹ 24.60
1.55%
Torrent Pharmaceuticals
TORNTPHARM
₹ 2,599.90
₹ 75.55
2.99%
₹ 1,972.30
- ₹ 3.60
-0.18%
Glenmark Pharmaceuticals Share Price
Glenmark Pharmaceuticals Ltd has a significant presence in the branded generics market in all emerging economies including India. The company entered the dermatology market with the launch of Candid cream. Glenmark's pioneering drug development focuses primarily on inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. The company's formulation business focuses on therapeutic areas, e.g. dermatology, infectious medicine, respiratory, cardiac, diabetes, gynecology, central nervous system and oncology. India is the organization's largest market region by revenue.
Glenmark Pharmaceuticals FAQs
How to Buy Glenmark Pharmaceuticals Share?
To purchase Glenmark Pharmaceuticals shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Glenmark Pharmaceuticals (ticker symbol: glenmark) on the trading platform provided by your broker and purchase the shares.
What's Glenmark Pharmaceuticals share price today?
The stock price of Glenmark Pharmaceuticals as of 10 May 2024 is ₹1,023.95
What is the Market Cap of Glenmark Pharmaceuticals?
Market capitalisation represents the total market value of a company's outstanding shares. As of 10 May 2024, Glenmark Pharmaceuticals (ticker symbol: glenmark) has a market capitalisation of approximately ₹1,18,60,93,84,374.60
What is the PE and PB ratio of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals Ltd's price-to-book ratio as of 10 May 2024 is 1.0605962, reflecting the market's valuation compared to its asset value. As of 10 May 2024, the trailing twelve months P/E (price-to-earnings) ratio is 9.748197, indicating the market values the company at around ₹9.75 for every ₹1 of earnings
What is the 52 Week High and Low of Glenmark Pharmaceuticals Share?
Glenmark Pharmaceuticals Ltd (glenmark) hit its 52-week high at ₹1,098.00, and its 52-week low at { ₹564.25}.